Marty is SVP, Global Head of Digital Medicine & Regulatory Innovation at EVERSANA, where he helps companies understand the dynamic landscape within digital medicine as they approach regulatory authorities and seek to commercialize their products.

He is a digital medicine and digital therapeutics veteran who has developed and launched innovative products targeting oncology, Alzheimer’s, autoimmune disease, and asthma via various regulatory and commercial pathways, has designed digital therapeutics clinical trials and commercial pilot studies, and has supported more than 50 companies over the past two years on regulatory strategy, regulatory submissions, policy, reimbursement, and commercial strategy.  As an indicator of his passion for innovation in digital medicine, he has been granted more than 10 breakthrough device designations by FDA for digital therapeutics and digitally-enabled medical devices.

CHEN KAISHEN, CEO of CinoCore and Deputy Chair of China Medical Device Association.

CHEN has led various initiates in digital health in China, including:

The 1^st oncology digital therapeutics product launch (SaMD), oral presentation of remote care in WCLC, MyPKFiT China planning (R&D and commercialization)

Prior to CinoCore, CHEN played key roles in Strategy Consulting, Biotech, and Big Data Company.

CinoCore has been DTA member since 2021.CinoCore was founded in 2020 with the mission of managing cancer as a chronic disease. CinoCore designs and develops clinically-validated software to actively engage oncology patients and physicians for remote monitoring, intervention, and lifestyle management for better clinical outcomes.